Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

Hair loss in Telogen effluvium is often chronic, linked to stress, and lacks a confirmed treatment, but topical corticosteroids may be used.

Alfredo Rebora suggests a simpler classification for hair loss and a new test for easier diagnosis.

Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.

The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.

People with hair loss conditions may also have thyroid disorders, but more research is needed to understand the connection.

Steroid treatment improved both gut and nerve symptoms in a man with Cronkhite–Canada syndrome.

Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.

Scalp biopsies from dermatomyositis patients show chronic hair loss without scarring, with mucin and blood vessel changes being very common.

Different hair diseases affect people during childbearing years, with treatments ranging from medication to psychological support.

The new hair loss treatment kit was safe and improved hair growth without any adverse effects.

A 68-year-old woman with lupus and blood disorders improved after increased steroids and immunoglobulin treatment.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

There is no standard treatment for the rare Cronkhite–Canada syndrome, which can be fatal and lead to cancer.

Autoimmune liver diseases are likely linked to certain skin conditions like vitiligo and psoriasis.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

The document concludes that managing skin conditions during pregnancy is important and requires specialized care.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.

Some skin diseases and their treatments can negatively affect male fertility.

A woman lost over 80% of her hair due to a condition called telogen effluvium after having COVID-19.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Blocking interferon-gamma might help treat various autoimmune diseases.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Early diagnosis, intensive therapy, and careful follow-up are crucial for managing overlapping TTP and SLE.

Levothyroxine is less effective in men with early-onset male-pattern baldness.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

People with polycystic ovary syndrome have a higher chance of having chronic thyroiditis.